Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma

Oncogene

Volumn 30, Issue 23, 2011, Pages 2622-2632

  Perier, A ^a   Fregni, G ^a   Wittnebel, S ^b   Gad, S ^b   Allard, M ^c   Gervois, N ^c   Escudier, B ^b   Azzarone, B ^d   Caignard, A ^a  

^a INSTITUT COCHIN   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Team 12   (France)

^d INSERM   (France)

Author keywords

immunotherapy; NK cells; renal cell carcinoma; von Hippel Lindau mutation

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2A; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANTIGEN RECOGNITION; ARTICLE; CLEAR CELL CARCINOMA; CYTOKINE RELEASE; CYTOLYSIS; HUMAN; HUMAN CELL; IMMUNOGENICITY; KIDNEY CARCINOMA; LOSS OF FUNCTION MUTATION; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; GENETIC COMPLEMENTATION TEST; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERFERON-ALPHA; INTERFERON-GAMMA; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MUTATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; RNA INTERFERENCE; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 79958295847     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.638     Document Type: Article

References (54)

1. Aggelis V, Craven RA, Peng J, Harnden P, Cairns DA, Maher ER et al. (2009). Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. Proteomics 9: 2118-2130.
2. Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, Blay JY. (2004). IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 111: 653-661. (Pubitemid 39062886)
3. Atkins D, Ferrone S, Schmahl GE, Storkel S, Seliger B. (2004). Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171: 885-889. (Pubitemid 38090527)
4. Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S. (2009). Treatment selection for patients with metastatic renal cell carcinoma. Cancer 115: 2327-2333.
5. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D et al. (2006). Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66: 2000-2011.
6. Braud V, Allan D, O'Callaghan C, Soderstrom K, D'Andrea A, Ogg G et al. (1998). HLA-E binds to natural killer cell receptors CD94/ NKG2A, B and C. Nature 391: 795-799. (Pubitemid 28099678)
7. Chatterjee-Kishore M, Wright KL, Ting JP, Stark GR. (2000). How Stat1 mediates constitutive gene expression: a complex of unpho-sphorylated Stat1 and IRF1 supports transcription of the LMP2 gene. EMBO J 19: 4111-4122. (Pubitemid 30608549)
8. Chuang SS, Kumaresan PR, Mathew PA. (2001). 2B4 (CD244)-mediated activation of cytotoxicity and IFN-gamma release in human NK cells involves distinct pathways. J Immunol 167: 6210-6216. (Pubitemid 33081549)
9. Cozar JM, Canton J, Tallada M, Concha A, Cabrera T, Garrido F et al. (2005). Analysis of NK cells and chemokine receptors in tumor infiltrating CD4T lymphocytes in human renal carcinomas. Cancer Immunol Immunother 54: 858-866. (Pubitemid 40991328)
10. Donskov F, Bennedsgaard KM, Von Der Maase H, Marcussen N, Fisker R, Jensen JJ et al. (2002). Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 87: 194-201.
11. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA et al. (1994). Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3: 2169-2173.
12. Gad S, Lefevre SH, Khoo SK, Giraud S, Vieillefond A, Vasiliu V et al. (2007). Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer 96: 336-340. (Pubitemid 46160640)
13. Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S et al. (2004). Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 109: 393-401. (Pubitemid 38252768)
14. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS et al. (2008). DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 205: 2965-2973.
15. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H et al. (1994). Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90. (Pubitemid 24232386)
16. Gobin SJ, van den Elsen PJ. (2000). Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol 61: 1102-1107. (Pubitemid 32043886)
17. Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. (2004). Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23: 5624-5631. (Pubitemid 39093040)
18. Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED et al. (2001). Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61: 6838-6845. (Pubitemid 32896508)
19. Ivanov SV, Salnikow K, Ivanova AV, Bai L, Lerman MI. (2007). Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13. Oncogene 26: 802-812.
20. Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI. (2001). Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. J Biol Chem 276: 15306-15315.
21. Kilburn BA, Wang J, Duniec-Dmuchowski ZM, Leach RE, Romero R, Armant DR. (2000). Extracellular matrix composition and hypoxia regulate the expression of HLA-G and integrins in a human trophoblast cell line. Biol Reprod 62: 739-747. (Pubitemid 30118317)
22. Kopper L, Timar J. (2006). Genomics of renal cell cancer-does it provide breakthrough? Pathol Oncol Res 12: 5-11.
23. Lahn M, Fisch P, Kohler G, Kunzmann R, Hentrich I, Jesuiter H et al. (1999). Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma. Eur Urol 35: 70-80. (Pubitemid 29080554)
24. Lanier LL. (2000). Turning on natural killer cells. J Exp Med 191: 1259-1262. (Pubitemid 30227114)
25. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML et al. (1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320. (Pubitemid 23231974)
26. Linehan WM, Pinto PA, Bratslavsky G, Pfaffenroth E, Merino M, Vocke CD et al. (2009). Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 115: 2252-2261.
27. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. (2004). Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5: 1260-1265. (Pubitemid 41057741)
28. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275. (Pubitemid 29246458)
29. Min JH, Yang H, Ivan M, Gertler F, Kaelin Jr WG, Pavletich NP. (2002). Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 296: 1886-1889. (Pubitemid 34596278)
30. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari M et al. (2001). Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19: 197-223. (Pubitemid 32368034)
31. Moretta L, Moretta A. (2004). Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23: 255-259. (Pubitemid 38294490)
32. Mouillot G, Marcou C, Zidi I, Guillard C, Sangrouber D, Carosella ED et al. (2007). Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 68: 277-285. (Pubitemid 46509544)
33. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C et al. (1998). Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338: 1272-1278. (Pubitemid 28216581)
34. Osborne A, Tschickardt M, Blanck G. (1997). Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter. Nucleic Acids Res 25: 5095-5102. (Pubitemid 28022275)
35. Parker AS, Cheville JC, Lohse CM, Igel T, Leibovich BC, Blute ML. (2005). Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma. Urology 65: 1090-1095. (Pubitemid 40824895)
36. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N et al. (2008). Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 123: 395-400. (Pubitemid 351842025)
37. Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, Collet N et al. (2009). Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer 101: 1417-1424.
38. Rajagopalan S, Fu J, Long EO. (2001). Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J Immunol 167: 1877-1881. (Pubitemid 32747490)
39. Reefman E, Kay JG, Wood SM, Offenhauser C, Brown DL, Roy S et al. (2010). Cytokine secretion is distinct from secretion of cytotoxic granules in NK cells. J Immunol 184: 4852-4862.
40. Rini BI, Campbell SC, Escudier B. (2009). Renal cell carcinoma. Lancet 373: 1119-1132.
41. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Grone EF et al. (2006). Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 12: 718-725. (Pubitemid 43259850)
42. Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ et al. (2003). Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 106: 905-912. (Pubitemid 37071669)
43. Segerer S, Henger A, Schmid H, Kretzler M, Draganovici D, Brandt U et al. (2006). Expression of the chemokine receptor CXCR1 in human glomerular diseases. Kidney Int 69: 1765-1773. (Pubitemid 43739203)
44. Seliger B, Maeurer MJ, Ferrone S. (2000). Antigen-processing machinery breakdown and tumor growth. Immunol Today 21: 455-464.
45. Smits KM, Schouten LJ, van Dijk BA, Hulsbergen-van de Kaa CA, Wouters KA, Oosterwijk E et al. (2008). Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 14: 782-787. (Pubitemid 351231160)
46. Urcan E, Haertel U, Styllou M, Hickel R, Scherthan H, Reichl FX. (2009). Real-time xCELLigence impedance analysis of the cytotoxi-city of dental composite components on human gingival fibroblasts. Dent Mater 26: 51-58.
47. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S et al. (2005). Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 174: 1338-1347.
48. Whaley JM, Naglich J, Gelbert L, Hsia YE, Lamiell JM, Green JS et al. (1994). Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 55: 1092-1102. (Pubitemid 24355562)
49. Wittnebel S, Da Rocha S, Giron-Michel J, Jalil A, Opolon P, Escudier B et al. (2007). Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. Cancer Res 67: 5594-5599. (Pubitemid 46991962)
50. Wysocki PJ, Kazimierczak U, Suchorska W, Kotlarski M, Malicki J, Mackiewicz A. (2010). Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Ther 17: 465-475.
51. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P et al. (2003). Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127-3132. (Pubitemid 46606294)
52. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K et al. (2002). VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94: 1569-1575. (Pubitemid 35277281)
53. Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA et al. (2005). Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 85: 328-341. (Pubitemid 40333150)
54. Zhu J, Wang X, Xu X, Abassi YA. (2006). Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J Immunol Methods 309: 25-33. (Pubitemid 43190799)